1. Hauser KF, Aldrich JV, Anderson KJ, Bakalkin G, Christie MJ, Hall ED, Knapp PE, Scheff SW, Singh IN, Vissel B, Woods AS, Yakovleva T, Shippenberg TS. Pathobiology of dynorphins in trauma and disease. Front Biosci. 2005;10:216–35.
2. Silberring J, Castello ME, Nyberg F. Characterization of dynorphin A-converting enzyme in human spinal cord. An endoprotease related to a distinct conversion pathway for the opioid heptadecapeptide? J Biol Chem. 1992;267:21324–8.
3. Magnusson K, Hallberg M, Bergquist J, Nyberg F. Enzymatic conversion of dynorphin A in the rat brain is affected by administration of nandrolone decanoate. Peptides. 2007;28:851–8.
4. Oka T, Aoki K, Kajiwara M, Ishii K, Kuno Y, Hiranuma T, Matsumiya T. Inactivation of [Leu5]-enkephalin in three isolated preparations: relative importance of aminopeptidase, endopeptidase-24.11 and peptidyl dipeptidase A. NIDA Res Monogr. 1986;75:259–62.
5. Hiranuma T, Kitamura K, Taniguchi T, Kanai M, Arai Y, Iwao K, Oka T. Protection against dynorphin-(1-8) hydrolysis in membrane preparations by the combination of amastatin, captopril and phosphoramidon. J Pharmacol Exp Ther. 1998;286:863–9.